Evalution of Flunisolide Nasal Solution in the Symptomatic Treatment of Perennial Rhinitis

Warland, A.

doi:10.1111/j.1398-9995.1982.tb02320.x

Cited by 10 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study reported that, similarly to allergic rhinitis, nearly half patients with NARES have bronchial hyperresponsiveness as assessed by methacholine challenge [ 26]. The results of the present study seem more in agreement with an allergic origin, since loratadine, which showed anti‐allergic activity, particularly on the effector cells, achieved an improvement of the clinical benefit attained with flunisolide, a topical steroid with demonstrated efficacy on NARES [ 27]. Also, flunisolide has an effect in all kinds of noninfectious rhinitis because of the typical antinflammatory action of corticosteroids, not restricted to just allergic inflammation.…”

Section: Discussionsupporting

confidence: 77%

A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES)

Purello-D'Ambrosio

Isola

Ricciardi

et al. 1999

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES)

Purello-D'Ambrosio

Isola

Ricciardi

et al. 1999

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…In total, 9 applicable articles were identified: 8 aqueous studies [12][13][14][15][16][17][18]20 and 1 nonaqueous study. 19 The symptoms evaluated were PND, [12][13][14][15][16] facial pain/pressure/headache, 17,18 and cough. 19,20 Data from an itemized assessment of the risk of bias for the 9 studies are presented in Figure 2.…”

Section: Resultsmentioning

confidence: 99%

“…The association between symptoms of interest and treatment with nasal steroid sprays was evaluated across all studies. [12][13][14][15][16][17][18][19][20]…”

Section: Methodsmentioning

confidence: 99%

Effect of Intranasal Corticosteroids on Secondary Sinonasal Symptoms: A Systematic Review of Randomized Trials

Deot

Barr

Mankowski

et al. 2019

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background Intranasal corticosteroid (INCS) sprays are indicated for use in the treatment of seasonal and perennial allergic rhinitis and include aqueous and nonaqueous formulations. Secondary symptoms of rhinitis include postnasal drip, facial pain/pressure, headache, cough, and ear fullness. The effectiveness of INCS on these specific symptoms, as well as the comparative effectiveness of aqueous and nonaqueous formulations, is poorly defined. Objective To evaluate the effectiveness of aqueous versus nonaqueous INCS formulations on less common sinonasal symptoms. Methods A systematic review was conducted of English-language, randomized controlled trials, with adherence to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) standard. Studies that did not provide quantitative data on relief of postnasal drip, facial pain/pressure, headache, cough, and ear fullness were excluded. An itemized assessment of the risk of bias was conducted for each included study. Results Of the 118 studies identified, 9 met the criteria for qualitative analysis. An effect on postnasal drip was reported in 5 studies, facial pain/pressure in 2 studies, and cough in 2 studies. A reduction in a specific symptom was reported in about half of these studies, with heterogenous outcome measures. Only 1 study reported the effect of a nonaqueous formulation on a specific symptom. No studies reported an effect on aural fullness. Conclusions Limited data are available regarding the effectiveness of aqueous or nonaqueous INCS on secondary symptoms in adult patients with rhinitis. Further study is needed using homogenous outcome measures and direct comparison of INCS formulations.

show abstract

“…Intranasally administered corticosteroids are the oral drug. In the aforementioned dosages, now recognized as effective agents in the thera-however, dexamethasone was associated with py of allergic rhinitis (3,4,5,7,10,11) yet litde adrenal suppression (1) by both routes, data is available concerning the relative contri-Since this study was completed there have bution of topical versus systemic drug effects in been no further published reports addressing the relief of symptomatology.…”

mentioning

confidence: 99%

A Comparison of Intranasal and Oral Flunisolide in the Therapy of Allergic Rhinitis

Kwaselow

McLean

Busse

et al. 1985

Allergy

View full text Add to dashboard Cite

Intranasal flunisolide is an effective treatment for allergic rhinitis. Flunisolide has high bioavailability when administered to normal subjects (50% of an intranasal dose reaches the systemic circulation) with minimal systemic effects. Bioavailability in patients with active rhinitis averages 62.4 +/- 15.7%. The oral dose bioequivalent to 100 micrograms intranasally is 500 micrograms. To define the comparative trial and systemic effects of intranasal flunisolide in patients with active allergic rhinitis, a multicenter, randomized, double-blind, placebo-controlled study was conducted during the 1983 ragweed hayfever season. Ninety-nine patients with ragweed hayfever for greater than or equal to 2 years and positive prick skin tests to ragweed were randomly allocated to one of three treatment groups: 0 = oral flunisolide 500 micrograms b.i.d. and intranasal placebo b.i.d.; N = intranasal flunisolide 50 micrograms per nostril b.i.d. and oral placebo b.i.d.; P = intranasal and oral placebo b.i.d. Treatment continued for 4 weeks. Patients kept daily symptom scores. Patients were evaluated by a blinded observer every 2 weeks and were globally evaluated at the study's end. Data were analyzed for each center and pooled. There were no significant differences in symptom severity of sneezing, nasal congestion, and throat itch in the 0 (oral flunisolide) and P (placebo) groups. N (nasal flunisolide) was significantly more effective than O or P (P less than or equal to 0.005) for each symptom for at least one 2-week period. Global evaluation demonstrated control of overall hayfever severity for N (nasal flunisolide) but not for O (oral flunisolide). We conclude that the therapeutic efficacy of flunisolide is achieved by topical and not by systemic action.

show abstract

Evalution of Flunisolide Nasal Solution in the Symptomatic Treatment of Perennial Rhinitis

Cited by 10 publications

References 12 publications

A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES)

A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES)

Effect of Intranasal Corticosteroids on Secondary Sinonasal Symptoms: A Systematic Review of Randomized Trials

A Comparison of Intranasal and Oral Flunisolide in the Therapy of Allergic Rhinitis

Contact Info

Product

Resources

About